Michael Ciesielski, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Circulating CD9-GFAP-survivin exosomes during active specific…
Browsing: Acute Lymphoblastic Leukemia
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives her input on when patients should stop treatment. She…
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains how this clinical trial now allows clinicians and other…
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center discusses the treatment trends for 2017 in thoracic oncology. This…
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of her presentation which discussed a five-year…
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the impact of her clinical trial on current clinicians…
Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of some of the presentations that were…
Peter Albers, MD, from the Heinrich-Heine-University Düsseldorf, Germany, explains that there is a big debate on whether robots should be…
Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute, London, UK, discusses how checkpoint inhibitors can be used earlier…
Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute, London, UK, gives an overview of the use of checkpoint…
Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the current landscape and future direction of…
Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the clinical implications of circulating tumor cell…
Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the clinical utility of circulating tumor cells…
Rong Na, MD, from the Huashan Hospital, Fudan University, Shanghai, China discusses germline mutations in prostate cancer at the European…
Peter Albers, MD, from the Heinrich-Heine-University Düsseldorf, Germany, discusses which factors are important to consider in surgical robots at the…
Jame Abraham, MD of Cleveland Clinic discusses his hopes for NSABP-FB10 becoming a Phase II and Phase III trial for…
Jame Abraham, MD of Cleveland Clinic gives an overview of his abstract, NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab…
Jame Abraham, MD of Cleveland Clinic discusses the key finding from his study shows the impact of neratinib for breast…
Jame Abraham, MD of Cleveland Clinic states that although breast cancer treatment has yet to include immunotherapy, it is still…
Jame Abraham, MD of Cleveland Clinic discusses the treatment trends for breast cancer, which include PARP inhibitors, CDK 4/6 Inhibitors,…
Mohamed Abazeed, MD, PhD of Cleveland Clinic explains the determinants of what allows tumor samples to be released into the…
Mohamed Abazeed, MD, PhD of Cleveland Clinic explains the need for a genomic encyclopedia for radiation oncology. He argues that…
Mohamed Abazeed, MD, PhD of Cleveland Clinic discusses his speciality, radiation oncology, and the treatment trends he sees for 2017.…
Mohamed Abazeed, MD, PhD of Cleveland Clinic discusses Joe Biden’s address to AACR and the importance of receiving funding from…
Mohamed Abazeed, MD, PhD of Cleveland Clinic discusses the impact of his panel discussion and his hopes towards the ability…
Mohamed Abazeed, MD, PhD of Cleveland Clinic gives an overview of his panel discussion, Radiation Science and Medicine Working Group…
In this roundtable discussion, Drs. Gerald Prager, Tanios Bekaii-Saab, and Eric Van Cutsem examine the safety and efficacy profiles of…
In this Key Insights activity, Dr. Scott Kopetz and conference chair David H. Ilson discuss the key non-colorectal cancer-related take-home…
In this Key Insights activity, Dr. Scott Kopetz and conference chair Axel Grothey discuss the key colorectal cancer-related take-home messages…
Recorded on site during the 18th European CongressL Perspectives in Lung Cancer, this activity features conference chairs Giorgio V. Scagliotti,…
Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK discusses the value of MRI…
Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the joint meeting of the EAU and Japanese Urological Association…
Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the limitations of magnetic resonance imaging (MRI) in prostate cancer…
Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the implications of earlier immune-oncology treatments for multidisciplinary…
Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the currently available androgen deprivation therapies (ADT) at the European…
Christian Stief, MD, from Ludwig-Maximilians-University, Munich, Germany discusses results from the ProtecT trial in prostate cancer at the European Association…
Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, speaks about highlights from the session on advanced prostate cancer at…
Maurizio Brausi, MD, from the AUSL Modena, B. Ramazzini Hospital, Modena, Italy, discusses clinical trials of robotic surgery in radical…
Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK discusses the value of videos…
Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the advantages of using imaging information for prostate cancer diagnosis…
Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, gives an overview of checkpoint inhibitors for urothelial carcinoma…
In this presentation from Lymphoma & Myeloma 2016, Dr. Kelly M. Trevino discusses strategies to focus on quality of life…
In this presentation from Lymphoma & Myeloma 2016, Dr. Jeremy S. Abramson argues for the use of novel agents for…
In this presentation from Lymphoma & Myeloma 2016, Dr. David G. Maloney argues for stem cell transplant for a 60…
In this presentation from Lymphoma & Myeloma 2016, Dr. Jeremy S. Abramson discusses the latest novel agents for the treatment…
In this presentation from Lymphoma & Myeloma 2016, Jia Ruan discusses the most promising new approaches and agents for the…
In this presentation from Lymphoma & Myeloma 2016, Dr. Kieron Dunleavy discusses the latest developments in the upfront and relapsed…
In this presentation from Lymphoma & Myeloma 2016, Dr. Sonali M. Smith discusses whether or not one should utilize cell…
In this presentation from Lymphoma & Myeloma 2016, Dr. George P. Canellos discusses the past, present, and future of Hodgkin…
How should we approach the adolescent/young adult Hodgkin lymphoma patient? Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.